Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
27 May 2020Website:
http://vincerx.comNext earnings report:
07 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 20:02:52 GMTDividend
Analysts recommendations
Institutional Ownership
VINC Latest News
Vincerx Pharma (VINC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
While initial findings for Vincerx's (VINC) new drug did indicate some effectiveness against tumors, the stock price fell after analysts expressed disappointment with the results.
Shares of Vincerx Pharma (NASDAQ: VINC) are dropping significantly on Tuesday following the release of initial data from a Phase 1 clinical trial. The early study results showed promise for Vincerx Pharma's cancer therapies.
Management to host virtual investor event on April 8 to highlight preliminary Phase 1 Data for VIP236, our first-in-class small molecule-drug conjugate (SMDC) Management to host virtual investor event on April 8 to highlight preliminary Phase 1 Data for VIP236, our first-in-class small molecule-drug conjugate (SMDC)
VIP943 poster supports selectivity and safety of lead CD123 ADC, VIP943, currently in Phase 1 VIP924 poster shows this novel CXCR5-ADC compares favorably with other ADCs in clinical development Enitociclib poster expands potential clinical indications PALO ALTO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it will present three posters related to VIP943 (NCT06034275), VIP924 (in preclinical studies), and enitociclib (in collaboration with University of Calgary) at the 65th American Society for Hematology Meeting (ASH), taking place in San Diego California from December 9 to 12, 2023.
Vincerx Pharma shares moved higher after the biopharmaceutical company announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration to commence a clinical trial of its investigational therapeutic VIP943 for patients with acute myeloid leukemia and myelodysplastic syndrome.
What type of business is Vincerx Pharma?
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
What sector is Vincerx Pharma in?
Vincerx Pharma is in the Healthcare sector
What industry is Vincerx Pharma in?
Vincerx Pharma is in the Biotechnology industry
What country is Vincerx Pharma from?
Vincerx Pharma is headquartered in United States
When did Vincerx Pharma go public?
Vincerx Pharma initial public offering (IPO) was on 27 May 2020
What is Vincerx Pharma website?
https://vincerx.com
Is Vincerx Pharma in the S&P 500?
No, Vincerx Pharma is not included in the S&P 500 index
Is Vincerx Pharma in the NASDAQ 100?
No, Vincerx Pharma is not included in the NASDAQ 100 index
Is Vincerx Pharma in the Dow Jones?
No, Vincerx Pharma is not included in the Dow Jones index
When does Vincerx Pharma report earnings?
The next expected earnings date for Vincerx Pharma is 07 August 2024